- ISIN
- US0223071020
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 28, 2024
Highlights
- Market Cap
- $3.08B
- Enterprise Value
- $3.05B
- EPS (TTM)
- -$2.31
- Total Revenue (TTM)
- $8.40M
- Gross Profit (TTM)
- $5.79M
- EBITDA (TTM)
- -$411.89M
- Year Range
- $2.80 - $30.60
- Target Price
- $38.44
- ROA (TTM)
- -35.35%
- ROE (TTM)
- -41.87%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALMS Performance Chart
Alumis Inc (ALMS) is up 152.1% since the beginning of the year. At $25 per share, ALMS is trading 19.6% below its 52-week high of $31.
Loading charts...
Returns By Period
Alumis Inc (ALMS) has returned 152.05% so far this year and 760.14% over the past 12 months.
Alumis Inc
- 1D
- 5.08%
- 1M
- 11.72%
- YTD
- 152.05%
- 6M
- 120.04%
- 1Y
- 760.14%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ALMS Monthly Returns History
Based on dividend-adjusted daily data since Jun 28, 2024, ALMS's average daily return is +0.35%, while the average monthly return is +7.27%. At this rate, an investment would double in approximately 0.8 years.
Historically, 48% of months were positive and 52% were negative. The best month was Jan 2026 with a return of +151.1%, while the worst month was Feb 2025 at -37.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.
On a daily basis, ALMS closed higher 49% of trading days. The best single day was Jan 6, 2026 with a return of +95.3%, while the worst single day was Apr 8, 2025 at -26.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 151.13% | 21.13% | -25.80% | 12.07% | -12.52% | 13.89% | 152.05% | ||||||
| 2025 | -4.83% | -37.83% | 32.04% | -32.57% | -15.46% | -14.29% | 38.00% | 12.08% | -14.01% | 19.05% | 61.47% | 27.25% | 24.17% |
| 2024 | -1.48% | -7.52% | 3.25% | -15.91% | 5.99% | -18.20% | -15.12% | -41.78% |
Benchmark Metrics
Alumis Inc has an annualized alpha of 108.77%, beta of 0.86, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since June 28, 2024.
- This stock captured 263.01% of S&P 500 Index gains and 198.03% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 108.77%
- Beta
- 0.86
- R²
- 0.02
- Upside Capture
- 263.01%
- Downside Capture
- 198.03%
Return for Risk
Risk / Return Rank
ALMS ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alumis Inc (ALMS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALMS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +4.26 | ||
| Sortino ratioReturn per unit of downside risk | +3.71 | ||
| Omega ratioGain probability vs. loss probability | 1.82 | 1.37 | +0.45 |
| Calmar ratioReturn relative to maximum drawdown | 20.94 | 2.78 | +18.15 |
| Martin ratioReturn relative to average drawdown | 54.87 | 12.44 | +42.43 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alumis Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alumis Inc was 79.26%, occurring on Jun 23, 2025. Recovery took 136 trading sessions.
The current Alumis Inc drawdown is 17.95%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -79.26%Jun 2025 | 12mo | 6mo 17d | 1y 6moJun 2024 - Jan 2026 |
2026 bear market2026 | -36.66%Jun 2026 | 3mo 11d | — | 3mo 26dFeb 2026 - now |
2026 correction2026 | -11.55%Jan 2026 | 1d | 20d | 21dJan 2026 - Feb 2026 |
2026 pullback2026 | -8.10%Jan 2026 | 1d | 5d | 6dJan 2026 - Jan 2026 |
2026 pullback2026 | -5.32%Feb 2026 | 3d | 2d | 5dFeb 2026 - Feb 2026 |
Drawdown Indicators
| ALMS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.26% | -56.78% | -22.48% |
Max Drawdown (1Y)Largest decline over 1 year | -36.66% | -9.10% | -27.56% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -17.95% | -1.80% | -16.15% |
Average DrawdownAverage peak-to-trough decline | -38.46% | -10.71% | -27.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.96% | 2.03% | +11.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alumis Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alumis Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALMS relative to other companies in the Biotechnology industry. Currently, ALMS has a P/S ratio of 300.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALMS in comparison with other companies in the Biotechnology industry. Currently, ALMS has a P/B value of 5.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALMS
Add Alumis Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALMS